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Summary
BACKGROUND 
 Yellow fever virus (YFV), a member of the genus Flaviviridae is the causative agent of 
YFD. The virus is classified as single-stranded RNA which is mostly transmitted by mosquitoes 
identified by  Walter Reed in the year 1900 as Aedes aegypti [4]. 
 In the past, Nigeria had been facing asporadic outbreaks of Yellow fever (YF), which 
began with the populous Northern region of the country. Aedes species of mosquitoes mainly 
transmit yellow fever virus (YFV) and vaccination is the only effective means of preventing it. 
OBJECTIVES
 This article presents a critical review and literature updates on the vector biology, YF 
vaccine immunodynamics and epigenetics of YFV, with the aim to understand the interplay of 
these factors in the re-emergence of YF and risk assessment of living or traveling to YF endemic 
areas. (in the year 2016-2018)
METHODOLOGY
 The live, attenuated viral strain of the 17D vaccine was administered to tourists and 
inhabitants of endemic regions of Africa (Figure: 2) and South America. Those eligible for the 
vaccine were usually given through routes of administration either by single subcutaneous or 
intramuscular injection. The vaccine (17D-204 strain) could be given either to infants (pediatric 
dosage) above 9 months or adults (adult dosage) using one dose of subcutaneous injection (≥4.74 
log10 plaque-forming units/0.5mL) not later than 10 days to regional migration
CONCLUSION
 Vectorial migration, jungle-to-urban spillover, immunization failure (especially 
in persons with chronic immune-mediated inflammatory diseases) and perhaps, genetic 
modification of YFV could be reasons for the resurgence of YF in the country. The single dose of 
the vaccine was usually sufficient to confer prolonged immunity against the infection but booster 
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Introduction
 In the year 1969 Yellow Fever disease (YFD) 
was first reported in Charleston, South Carolina, 
Philadelphia and Pennsylvania [1] while the most 
recent outbreak was reported in Brazil, Angola and 
DR of Congo from 2015 to 2018 [2,3]. 
 Yellow fever virus (YFV), a member of the 
genus Flaviviridae is the causative agent of YFD. The 
virus is classified as single-stranded RNA which is 
mostly transmitted mainly by mosquitoes identified 
by Walter Reed in the year 1900 as Aedes aegypti 
[4]. Based on the virus genotype, Yellow fever 
Virus (YFV) was classified into East African, West 
African, South American No. I, and South American 
No. II [5]. 
 The most common virus route of transmission  
was categorized into three, viz; 
(a) Sylvatic cycle, involving non-human primates 
(NHPs) which are infected by tree-dwelling 
mosquito vectors such as Haemagogus spp. and 
Sabethess pp. 
(b) Intermediate cycle, involving peridomestic Aedes 
species which act as a bridging point between 
humans and non-human primates. 
(c) Urban cycle,  involving humans are infected 
by Aedes spp. Mosquitoes that feed mostly on 
humans [6].
 Despite the success of the vaccine developed 
against the virus, YFV remain a threat to the general 
populations of the world due to low coverage of the 
vaccine and exposure to mosquito vector common 
in African and South American countries. Hence, 
suggesting that the disease outbreak can effectively be 
controlled by a vaccine supply and minimizing vector 
population [7]. 
 Recently 200,000 cases of YFD had been 
reported across African and South American region 
with 30,000 cases resulting in the death of the infected 
individuals. Yellow fever disease sudden re-emergence 
has been associated with travels of individuals to 
different parts of the world [1].
 This article presents a critical review and 
literature updates on the vector biology, vaccination 
immunodynamics and epigenetics of YFV with the aim 
to understand the interplay of these factors in the re-
emergence and risk assessment of living or travelling 
to YF endemic areas.
Global Distribution and 
Epidemiology of Yellow Fever
 Tropical and sub-tropical areas of South 
America and Africa are known for Yellow fever 
outbreaks from time to time. Globally, an estimated 
600 million people live in such endemic areas. About 
200,000 cases of disease and 30,000 deaths are 
recorded annually[8].
 As indicated by the World Health Organization 
(WHO) profile, Africa continent experience the vast 
majority of Yellow fever infection cases and deaths. In 
particular, Sub-Saharan Africa the disease is a major 
public health problem occurring in epidemic patterns. 
The periodic and yet unpredictable outbreaks of Yellow 
doses were often required based on endemic state of certain countries' Medical Laboratory Staff 
who frequently work on wild-type yellow fever virus. Based on regular exposure to this virus on 
routine basis, the neutralizing antibody titers against the virus are usually assessed every ten years 
to determine the necessity for booster doses of the 17D vaccine. Irrespective of the knowledge of 
neutralizing antibody titers for the virus, vaccination every 10 years is recommended especially for 
individuals frequently exposed to the vir
RECOMMENTATIONS
 Increase vaccination coverage. Include YF vaccine in childhood vaccination programs. 
Make effort to maintain and control future outbreaks. 
Keywords: Vaccination, Genetics, Yellow Fever, Re-emergence
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fever experienced in Africa, with a population of 610 
million people, among which more than 219 million 
reside in urban settings in 32 African countries were 
considered at risk of Yellow fever infection [8].
 South, Central American countries were 
Yellow fever endemic, and several Caribbean Islands 
were considered at high risk as well. Although the 
disease usually causes only sporadic cases and small 
outbreaks, nearly all major urban centers in the 
American tropics have been re-infested with Aedes 
aegypti and most urban dwellers are vulnerable. 
Immunization coverage  was low. The Latin American 
region was at that moment at greater risk of urban 
epidemics than within the past 50 years [8].
 The Aedes aegypti density and habitats had 
expanded in both urban and rural areas. The mosquito 
was once again infesting regions that it had been 
previously eradicated. This disease was reported to 
have originated from Africa and imported into the 
Americas, but became widely established there. Yellow 
fever has never been reported from many developed 
countries. Should it be accidentally imported, the 
potential for outbreaks exists because the appropriate 
mosquito vector is present [9].
 It had been estimated that, 90% of the outbreaks 
of YFD occur on the African continent [9]. 
(a) In 2008, Togo recorded the largest number of 
cases. 
(b) In 2016, Angola experienced a big outbreak and 
spread to neighbouring countries before the 
adoption of massive vaccination campaign that 
contained the disease. 
(c) In March and April 2016, China recorded and 
reported 11 cases, which in history was the first 
appearance of the disease in Asia [8,10].
 Seven genotypes of yellow fever viruses have 
been identified through Phylogenetic analysis, and they 
are assumed to be differently adapted to humans and 
to the vector A. aegypti. Five (5) genotypes (Angola, 
Central/East Africa, East Africa, West Africa I, and 
West Africa II) occur only in Africa. West Africa 
Genotype I is found in Nigeria and the surrounding 
areas [11].
 This appears to be especially virulent or 
infectious, as this type was often associated with 
major outbreaks. However, the 3 genotypes in East and 
Central Africa occurred in areas where outbreaks were 
rare. Two previous outbreaks in Kenya (1992–1993) 
and Sudan (2003 and 2005) involved the East African 
genotype, which had remained unknown until these 
outbreaks occurred [12].
 Two genotypes had been identified in 
South Africa (South American genotypes I and II) 
Phylogenetic analysis identified two genotypes that 
appear to have originated in West Africa, and were 
introduced into Brazil [13 - 15]. 
 Year 1882 appears to be the date of introduction 
into South America (95% confidence interval 1701 
to 1911). Between 1685 and 1690, historical record 
shows an outbreak of yellow fever in Recife, Brazil. 
Afterwards, the disease seems to have disappeared, 
until 1849 when the next outbreak occurred. The 
yellow fever virus was likely introduced with the 
importation of slaves from Africa through slave trade. 
Genotype I have been divided into five subclades, A 
through E [15, 16].
 In the late 2016, a large outbreak began in 
Minas Gerais state of Brazil that was characterized as 
a sylvan or jungle epizootic. The outbreak was believed 
to have begun in brown howler monkeys which was 
a sentinel species for yellow fever, then later spread 
to men that worked in the jungle. No case had been 
reported suggesting transmission between humans by 
the Aedes aegypti mosquito, that can sustain urban 
outbreaks that can spread rapidly.  [17, 18]
 The sylvan outbreak continued spreading 
towards the Brazilian coast that, in April 2017, where 
the predominant people were unvaccinated (more 
than 3,000 suspected cases, 758 were confirmed and 
264 deaths confirmed to be of yellow fever). The 
outbreak appeared to be declining by the end of May 
A vaccination campaign was launched by the Health 
Ministry and was concerned with the spread of the 
disease during the Carnival season in February and 
March. A level 2 alert was issued by the CDC(practice 
enhanced precautions) [19 - 22].
 According to Bayesian analysis of Genotypes 
I and II, it was shown that Genotype I accounts for 
virtually all the current infections in Brazil, Colombia, 
Trinidad, Tobago, and Venezuela, while Genotype II 
accounted for all cases in Peru [23]. Genotype I has 
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been documented to have originated around the year 
1908 in the Northern Brazilian region (95% Highest 
Posterior Density interval [HPD]; (1870–1936) while 
Genotype II in 1920 had originated in Peru (95% HPD: 
1867–1958). Both (Genotype I and II) have an estimated 
rate of mutation of about 5 × 10-4 substitutions/site/year, 
similar to that of other RNA viruses [21].
 The main vector (Aedes aegypti) is also found 
in tropical and sub-tropical regions of Asia, Australia 
and the Pacific, but yellow fever outbreak or case 
has never occurred there, until the recent 11 cases 
introduced by jet travel from the 2016 Angola and 
DR Congo yellow fever outbreak in Africa. Proposed 
explanations include;
(a) The fact that, the strains of the mosquito in the 
east were less able to transmit yellow fever virus
(b) That immunity was present in the populations 
because of other diseases caused by related 
viruses (for example, dengue),.
(c) That the disease was never introduced because 
the shipping trade was insufficient [24].
 But none of the explanations was considered 
satisfactory. Another proposal was the absence of 
slave trade to Asia on the scale similar to that of the 
Americas. The trans-Atlantic slave trade probably 
introduced yellow fever into the Western Hemisphere 
from Africa [25].
Yellow Fever Transmission
a. The urban cycle is most clearly delineated by the 
human environment and, thus, primarily involves 
A. aegypti mosquitoes since these were some 
of the most anthropophilic mosquitoes known. 
Humans forms the reservoir for this cycle, 
but since mosquitoes can transmit the virus 
transovarially they may also serve as a reservoir 
[26, 27].
b. The sylvan cycle (i.e. jungle cycle) involves two 
genera of-mosquitoes: Aedes and Haemagogus 
[8]. These mosquitoes transmit the virus 
primarily to non-human primates, which serve as 
the reservoir. Other mammals may be infected in 
this cycle but are not likely to be important for the 
maintenance of the viral ecology [27]. 
 These two cycles, the urban and the sylvan, 
occur in both South America and Africa and so 
are relevant transmission cycles in both macro-
regions[28]. The sylvan cycle in Africa requires 
A. africanus to maintain the viral ecology. 
However, the sylvan cycle in South America is 
the only transmission cycle that does not involve 
aedine mosquitoes. 
 In the South American sylvan cycle, Haemagogus 
mosquitoes are the critical vectors of yellow fever. 
They were particularly tropical forest mosquitoes, 
typically living their lives in the forest canopy [8]. 
When adapted to a somewhat narrower ecologic 
niche, these mosquito’s oviposition in tree holes, 
the crevices of tree bark, or within exposed 
bamboo stalks [27].
 The Haemogogus mosquitoes lay their eggs 
directly on the surface where the eggs, similar 
to the aedes mosquitoes, will mature once they 
are immersed in water following the next raining 
season [8]. 
 These mosquitoes transmit the virus primarily 
to non-human primates, especially those that 
occupy the canopy. Humans were at risk of 
infection in this transmission cycle when they 
come into contact with this forested habitat, 
particularly when that contact actually disrupts 
the habitat [29]. 
 This scenario arises with deforestation and the 
development of natural habitat for agricultural 
or resource extraction purposes. Transmission 
to humans via this cycle was typically limited to 
workers in industries that encounter this forested 
habitat, where sporadic cases, or occasionally, 
small-scale outbreaks are the norm [29].
 In the African sylvan cycle, the Haemagogus 
mosquitoes and Aedes africanus are analogues 
(Figure 1) [27].
 This mosquito has a similar ecology to the South 
American Haemagogus species by living in the 
forest canopy and taking blood meals primarily 
from non-human primates, which are reservoirs 
for the yellow fever virus. The A. africanus also 
mimics the ovipositioning of the Haemagogus 
mosquitoes. Therefore, transmission to humans 
in the African sylvan cycle also affects workers 
involved in deforestation, but is not limited to this 
population [27].
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 Consequently, conflict in some regions of sub-
Saharan Africa where the sylvan yellow fever 
was endemic exposed refugees and displaced 
communities to this cycle, ultimately resulting in 
more severe outbreaks in those setting than had 
been experienced in South America [30].
(c) The intermediate cycle (i.e. the savannah cycle, 
or the rural cycle) occurs only in Africa and 
involves several different species of Aedes 
mosquitoes in the transmission of the virus [31]. 
 As the name suggests, this cycle occurs in the 
landscape between the strictly forest, or sylvan cycle 
and the strictly domestic, or urban cycle. As such, 
the Aedes spp. involved typically obtain blood meals 
from both humans and monkeys. It is essentially an 
ecotonal cycle, wherein the geography of transmission 
is determined by landscapes of transition from one 
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Figure 1:   Transmission Cycle Between Yellow Fever Virus and Its Vector Source: Walsh [27].
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The Vector and the Landscape
 To begin, it must be emphasized that, this 
mosquito had a very particular preference for the water 
environment it selected for laying its eggs. It liked 
small containers that collect rainwater. The mechanics 
work as follows; 
That mosquito did not lay its eggs either in the 
water nor on the surface of the water, as most 
other species do [20]. Instead, A. aegypti lays its 
eggs above the water on the interior wall of the 
vessel containing water so that when the water 
vessel is refilled, from the water line at which 
the mosquito laid its eggs to the lip of the vessel, 
the eggs will have enough time to complete 
their developmental cycle to adulthood before 
evaporation depletes the water source. A truly 
incredible evolutionary adaptation [20].
 That mosquito was originally adapted to 
a forest habitat wherein it would seek out holes in 
trees that could regularly collect rainwater[32]. Tree 
holes were much more ubiquitous than you could 
expect in a forest (think woodpeckers), and so that 
was quite an effective niche for that mosquito. As 
humans encroached more and more on forest habitat 
establishing agriculture, building increasingly dense 
communities and living conditions, A. aegypti readily 
adapted to the new circumstances [32]. 
 The mosquitoes found an abundance of new 
and highly effective small containers strewn in and 
around households that could easily collect, or were 
intended to store water [33]. The mass production of 
plastics had been a major factor in the proliferation of 
potential water containers. Today A. aegypti is just as 
much an urban mosquito as it was a forest mosquito and 
probably more so. Likely, A. aegypti is now uniquely 
adapted to the human environment. 
 Unlike other mosquito species, they would 
often live in the household with humans and could 
complete their whole life cycle there. They also bite 
during the day, so they had unlimited access to humans 
for taking blood meals [33]. Finally, this mosquito's 
preferred host, as you might have already guessed, 
was humans. Since that mosquito was very effective 
at exploiting the human environment, it was also very 
effective at transmitting any viruses that it was capable 
of carrying and which were infective to humans.
Resurgence of Yellow Fever in 
Nigeria
 In Nigeria, although YF was endemic in the 
Western regions, it had become epidemic outside this 
zone in the previuos last 2 years. The YF transmission 
cycle occasionally re-emerges and, in the last decade, 
an increase in viral circulation had been observed 
throughout the country. 
 From January 2019 to November 2019, 3009 
suspected cases and 40 deaths. 10 laboratory confirmed 
cases an increase noticed in case fatality rate compared 
with 2018 (1.3% versus 0.0%) [34].
 Out of the suspected YF cases in Nigeria, the 
most conspicuous was on 29th August 2019, when a 
suspected yellow fever case was reported from Kano 
state with a travel history to Yankari game reserve, 
Alkaleri Local Government Area (LGA), Bauchi state, 
Nigeria.
 From 29th August through 22nd September 
2019, Nigeria reported an outbreak of yellow fever with 
an epi-centre in the Yankari game reserve of Alkaleri 
LGA, Bauchi state [33]. 
 According to Nigeria Centre for Disease 
Control (NCDC) [34], 231 suspected cases had been 
reported in four states including Bauchi (110), Borno 
(109), Gombe (10), and Kano (2), of which there had 
been 13 presumptive positive by IgM testing and 24 
cases positive by reverse-transcriptase polymerase 
chain reaction (RT-PCR) at national laboratories. 
 Of the 24 cases confirmed by RT - PCR (20 
cases in Bauchi, three in Gombe and one in Kano 
state), six deaths were reported, all from Alkaleri 
LGA, Bauchi state, resulting in a case fatality ratio 
of 25% among the confirmed cases. The vaccination 
history for the 231 suspected yellow fever cases was 
not known [34].
 Vaccination was the only effective measure 
to prevent YF. The rapid recognition of the disease 
outbreaks in high - risk areas, followed by the 
vaccination of 60% to 80% of the population was 
crucial to prevent epidemics [35]. 
 Generally, there were two vaccines available, 
derived from the same strain, with very similar and 
comparable response profiles and reactogenicity – 
African Journal of Health Sciences  Volume 32, Issue No. 5, September - October  201944
YFV 17DD (Biomanguinhos©) and 17D-204 (Sanofi 
Pasteur©)  The current Nigerian immunization schedule 
recommends a single subcutaneous 0.5 ml dose at nine 
months of age and is contraindicated in some groups, as 
follows; [36-37].
(a) Infants younger than nine months for routine 
immunization or younger than six months during 
an epidemic; 
(b) Pregnant women or breast feeding mothers, 
children under six months of age, except 
Figure 2: Areas with Risk of Yellow Fever Virus Transmission in Africa. (Source: CDC) [39].
during YF outbreaks, when the risk of 
infection is high.
(c) Severe allergies to egg protein.
(d) History of severe adverse reactions to previous 
doses.
(e) Organ transplantation
(f) Previous history of thymus disease 
(myastheniagravis, thymoma, thymus absence or 
surgical removal).
(g) Severe immunodeficiency of any nature.
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Yellow Fever Vaccination Protocol
 The live, attenuated viral strain of the 17D 
vaccine was available as the main commercially 
sourced yellow fever vaccine. It ensured highly 
effective and sustained immunity when administered 
to individuals with high risk of exposure to the wild-
type Yellow Fever virus. Those were especially tourists 
and inhabitants of endemic regions of Africa (Figure 
2) and South America. 
 Those eligible for the vaccine were usually 
given through routes of administration either by 
single subcutaneous or intramuscular injection. The 
administration of the vaccine (17D-204 strain) could 
be given either to infants (pediatric dosage) above 
9 months or adults (adult dosage) using one dose of 
subcutaneous injection (≥4.74 log10 plaque-forming 
units/0.5mL) not later than 10 days to regional 
migration [33,38]. 
 The single dose of the vaccine was usually 
sufficient to confer prolonged immunity against yellow 
fever infection but booster doses were often required 
based on endemic state of certain countries and in the 
following circumstances:
i. Migrants who intend to spend prolonged durations 
in highly endemic rural regions of West Africa 
especially during outbreak or peak transmission 
period [37].
ii. Medical Laboratory Staff who frequently work on 
wild-type yellow virus. Based on regular exposure 
to this virus on routine basis, the neutralizing 
antibody titers against the yellow fever virus are 
usually assessed every ten years to determine the 
necessity for booster doses of the 17D vaccine.
iii. Irrespective of the knowledge of neutralizing 
antibody titers for the virus, vaccination every 10 
years is recommended especially for individuals 
frequently exposed to the virus.
 These recommendations aid in effectively 
controlling yellow fever re-emergence and transmission 
to regions of low risk for the infection [39].
Mechanisms of Action of
D17 Vaccines
 The successful reputation of the 17D 
vaccine has accredited it to serve a unique model 
in understanding responses of the human immune 
system during an acute phase of viral infection. The 
antibodies, generated on exposure to these viruses, 
play dominant effect or mechanistic roles in ensuring 
prolonged, vaccine-induced protective immunity. 
Several innate and cellular mechanisms as well as the 
helper (CD4+) and cytotoxic (CD8+) T lymphocytes 
are known to respond in ways that contribute to the 
provision of lifelong protective immunity [38 -43].
 Although a holistic event of the mechanism 
of protective immunity against Yellow Fever is not 
completely understood, immunoglobulins are considered 
to be the major contributors in conferring protective 
vaccine-induced mechanism and their presence have 
been associated with protective immunity [44]. 
 Following a dose of immunization with the D17 
vaccine, pre-existing non-cognate CD4+ T-lymphocytes 
are induced to enhance immunoglobulin response to the 
target antigens coated onto the Yellow Fever 17D (YF-
17D) vaccine particles. These vaccine particles coated 
with target antigen also engage the B-cells with B-cell 
receptors (BCRs). 
 The B-cells internalize these antigen-coated 
vaccine particles within its endosomes with the release 
of proteases which disintegrate the antigens both on the 
vaccine surface and those entrapped within the vaccine 
particle to generate peptide fragments. 
 These fragments are presented on the major 
histocompatibility complex class II (MHC II) (Figure 
3) to cognate CD4+ T-lymphocytes (i.e. those that 
recognize the same antigen as the rare or weak B-cell 
epitomes) and non-cognate CD4+ T-lymphocytes (i.e. 
those that identify the strong helper MHC II receptors) 
[45]. 
 The pre-existing CD4+ T-lymphocytes that 
identify helper antigen generated either by Yellow Fever 
infection or pre-vaccination can induce co-stimulatory 
signals to B-cells which generates a plethora of 
neutralizing antibody titers, that is measurable in the 
vaccinated within 6-28 days after vaccination [45]. 
 These signals drive the proliferation, 
differentiation, immunoglobulin synthesis, somatic 
hypermutation, and isotype switching of B-cells. 
Due to the determination of the specificity of 
immunoglobulin response at the point of BCR-induced 
antigen identification, the immunoglobulins generated 
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Figure 3: Vaccine mechanism of action.     Source: Egliet al.[46].
Demerits of Yellow Fever Vaccines
 Despite the successes of the YF-17D, limitations 
and side effects were associated with the use of this 
vaccine. This vaccine was contra-indicated in infants 
less than 8 months of age except during the peak of 
yellow fever transmission. Other limitations associated 
with this vaccine include history of severe allergic 
response to egg or to any component of the vaccine, 
hypersensitivity to earlier dose of the vaccine, history 
of thymectomy, medication-induced immunodeficiency 
and HIV infection [50].
 Adverse effects associated with YF-17D 
vaccine included the Neurotropic and viscerotropic 
disorders but the YF-17D vaccine-associated 
Viscerotropic disease (YEL-AVD) was observed to be 
more lethal [38]. 
 Neutralizing antibody titers was known to 
persist in those vaccinated up to 45-60 years after 
immunization [47]. Kongsgaard and colleagues 
demonstrated that an average neutralizing (Plaque 
Reduction Neutralization Test) antibody titer of 1 : 1280 
(within 1 : 160 to 1:20,480) in those immunized after 
9-40 days following vaccination with YF-17D vaccine. 
That finding corroborated with an animal study 
involving either immunoglobulin transfers or genetical 
induction of immune deficiencies [47-49]. 
 In YF-17D vaccinated mice, protection was 
demonstrated around 5 - 7 days evident with the 
influx of specific cytotoxic (CD8+) T-cells. Reduction 
in CD8+ T-cell population correlated with reduced 
protective immunity and elevated organ viral load 
[49]. These selected studies synergistically reveal the 
efficiency of YF-17D vaccine in providing protective 
immunity in immunized individuals.
will be uniquely directed only against the target antigen on the YF-17D vaccine particle surface (figure 3).
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 Two unique patterns of YEL - AVD risk 
existence include:
i. Risk in younger individuals which mainly involve 
females with innate immunity defects in whom 
mortality rate is higher. 
ii. Risk in the elderly especially in males with age-
associated immune deterioration and relatively 
lower mortality rate.
 Viscerotropic disease related to YF - 17D 
vaccine was  rarely observed after first immunization 
with the vaccine. Within 10 days following vaccination, 
severe multi-organ failure resulted with a mortality 
rate in excess of 60%. Risk factors involved a history 
of thymectomy of thymoma and greater or equal to 60 
years of age. 
 Hence, Neurotropic disease related to YF - 17D 
vaccine, which   involved meningoencephalitis, acute 
disseminated encephalomyelitis and Guillain – Barré 
syndrome, have been reported in infants less than 6 
months of age and in individuals who were 60  and 
above years of age [50].
Risk for Travelers
 A traveler is at the risk for acquiring YF by 
various factors, including immunization status, travel 
location, season, duration of exposure, recreational 
and occupational activities while traveling, and local 
rate of virus transmission at the time of travel [34]. 
 Although reported cases of human disease 
were the principal indicator of disease risk, case reports 
might be absent because of a low level of transmission, 
failure of local surveillance systems to detect cases or 
a high level of immunity in the population (because of 
vaccination, for example) [51].
 Since “epidemiologic silence” does not mean risk 
absence, travelers are advised not go into endemic areas 
without vaccination or taking other protective measures 
[34].
 YF virus transmission was seasonal in rural 
West Africa, with an increased risk during the end 
of the rainy season and also the beginning of the dry 
season (usually July – October) [34]. 
 However, Ae. aegypti mosquito may transmit 
YF virus periodically, including dry season, in both 
rural and densely settled urban areas. During the 
rainy season (January – May, with a peak incidence in 
February and March), the risk for infection by sylvatic 
vectors in South America was highest [34]. From 1970 
through 2015, 11 cases of YF were reported in people 
who travelled to:
i. Risk  West Africa (6 cases)
ii. South America (5 cases) from the United States 
and Europe,
 Where 8 (73%) out of 11 infected travelers 
died. Only traveler who survived, had a history of YF 
vaccination documented. 
 From the year 2016, there was an increase in 
the number of travel-associated YF cases, primarily 
as a result of outbreaks in Angola and Brazil. Starting 
from 2016 through mid - 2018, more than 35 travel 
- associated cases were reported in unvaccinated 
travelers who were residents of non - endemic areas or 
countries. That included at least 13 European travelers 
and 1 American traveler to Peru [34].
 It is difficult to predict the risk of acquiring 
YF during travel because of variations in ecologic 
determinants of virus transmission. For a 2 - weeks 
stay, the risk for illness and death due to YF for an 
unvaccinated traveler visiting an endemic area was 
estimated as follows:
a. In West Africa, 50 out of 100,000 and 10 out of 
100,000, respectively. 
b. In South America, 5 out of 100,000 and 1 out of 
100,000, respectively [34].
 These estimations are based on the risk to 
native populations, often during the peak transmission 
season. These might not accurately reflect the risk 
to travellers with different immunity profiles, have 
less outdoor exposure and take precautions against 
mosquito bites. However, during an outbreak, there is a 
higher risk of infection for travellers, as demonstrated 
with recent outbreaks in Angola and Brazil [52].
Novel Control Measures against 
Yellow Fever: Prospects and 
Drawback
 Mosquito - borne viruses - such as Zika, 
Dengue Fever, chikungunya, and Yellow Fever, among 
others are of global concern. Although a vaccine 
development for the prevention of mosquito-borne 
arbovirus infections had been a focus, mitigation 
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strategies continue to rely on vector control. Failure 
to prevent recent epidemics and arrest expanding 
geographic spread of key Arboviruses, such as 
Dengue, had consequently increased the necessity to 
further improve current strategies within integrated 
approaches and advance development of innovative, 
and alternative strategies for the control of mosquito-
borne Arboviruses [53].
 The main approach for Arbovirus outbreak 
control (such as Dengue) was the use of synthetic 
chemicals with quick-action killing of adult vectors 
using space spraying.  The majority of recommended 
insecticides are of the pyrethroid chemical class, 
creating challenges to preventing selection pressure 
on susceptible mosquito populations as well as the 
control of pyrethroid-resistant vectors [54].
 In the management of arbovirus vector 
population, precisely of Ae. aegypti, larval control had 
long been proposed and implemented as a principal 
strategy, including applications of chemical and 
microbial larvicides, bacterial toxins and insect growth 
regulators (IGRs) [55-56].
     Biological agents used against immatures include 
predatory copepods, fish, and Toxorhynchites larvae. 
Arguably, the dependency to detect, access, and 
eliminate or treat domiciliary- often - cryptic - breeding 
sites, has been the greatest obstacle to Ae. aegypti larval 
control success, a challenging and costly task that often 
leads to low coverage.
  In addition, their widespread adoption is 
limited due to reduced efficiency in some occasions
[ 57]. 
Epigenetic Basis of Yellow Fever 
Resurgence
 The resurgence of Yellow Fever Virus (YFV) 
infection in recent times (in the year 2016-2018) had 
been attributed to low vaccination coverage. There 
was need to reconsider YFV as a serious threat to 
human health due to its re-emergence in non-endemic 
and endemic areas with a history of low vaccination 
coverage [58]. 
 
 Besides low vaccination coverage, other drivers 
existed that could result to YFV re-emergence in 
endemic and non-endemic areas such as: 
a. Risky global warming. 
b. Increased temperatures. 
c. Increased rainfall intensity.
d. Expansion of human activities to YFV-endemic 
areas.
e. Increase in human YFV circulation locally and 
cosmic rays particles [58].
f. Solar particles and electrically charged cometary 
dust particles including virions [59]. 
 The sylvatic (Haemaghogus Leucocelaenus 
and Sabethesalbiprivus) and urban (Aedes aegyti) 
transmission cycles are also important and crucial 
to the outbreaks [5, 60]. Therefore, there is need 
for further research elucidating the ecological 
connections between YFV, its vector, and its 
environmental niche so as to easily predict, anticipate 
and prevent future epidemics.
 This presented the opportunity to eradicate the 
disease from human population but not the non-human 
primate host of the virus. Children aged nine months 
and older were administered the YF 17D vaccine. Thus 
enjoying the life long immunity of the vaccine and 
reputation of being one of the safest and most effective 
live attenuated vaccine [61]. 
 YFV incidence reduced drastically and there 
were relatively few cases within 25 years span, with 
outbreaks limited to countries that did not administer 
the vaccines. As the sense of complacency and feeling 
that YF was beaten begins to set in, the effort to 
maintain and control future outbreaks was abandoned. 
 The YF vaccine was also not included in 
the childhood vaccination programs and therefore, 
individuals born after the vaccination programs were 
not vaccinated with young individuals who enter the 
jungle areas for employment were vulnerable to the 
infection. 
 In the late 1950s and early 1960s, there were 
several outbreaks in Africa, with the highest incidences 
in the Western region The number of cases continue 
to increase as a result of replacement of the routine 
vaccination campaigns with the emergency vaccination 
campaigns once an outbreak has been identified. 
Once the outbreak ceases, so does the vaccination. 
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This is clearly not a cost - effective mechanism to 
control a vaccine-preventable disease. As for the YF 
resurgence in the Americas, the YF vector (Aedes 
aegypti) returned to the South American countries 
after elimination in the 1930s and 1940s as a result of 
abandoned control measures [61]. 
 Today, the vector mosquito infests a larger 
area of the Americas more than before its temporary 
elimination as a result of global warming and political 
decisions not to continue with mosquito-control 
programs[13]. Densely populated coastal regions of 
Brazil have become re-infested with Aedes aegypti 
leading to concerns about the resurgence of Urban YF. 
The South East region of Brazil has experienced the 
largest YF outbreak in Latin America in decades, which 
began in 2016 and it was spreading eastwards of the 
country. 
 Although poor hygiene and climate change 
were cited as the causes, other fundamental risk 
factors coexist such as cosmic rays, solar particles and 
electrically charged cometary dust particles including 
virions [59]. 
 Cosmic rays have been well documented to 
cause genetic changes. In recent times, it has been 
discovered that there was a decrease in the Earth’s 
magnetic fields in the Southern Hemisphere, straddling 
land masses in South America and Africa. European 
Space Agency (ESA) have recently released a new data 
that reveals that, our geomagnetic field was weakening 
by around 5% a year, which is ten times faster than it 
was previously estimated [59]. The vector mosquito 
responsible for these viral diseases is sensitive to the 
geomagnetic field, and a weakening in the field can 
increase the mosquitoes reproductive speed and density. 
 In January 2015, Mexico recorded a sudden 
increase of cosmic rays, as revealed by the World Data 
Centre for Cosmic Rays (WDCCR) and continued 
throughout the year and that was probably the cause of 
the ZIKV and YF outbreaks [61].  
Conclusion
 An ongoing sporadic outbreak of yellow fever 
in Nigeria began in 2018. The outbreak has now spread 
throughout the country. The Nigerian Ministry of 
Health had reported cases of the disease in all 36 states 
and the Federal Capital Territory. The large disparity 
in yellow fever incidence and mortality that currently 
exist between Africa and the Americas is largely due 
to the massive vaccination campaigns that have been 
undertaken in many countries in South America, which 
had thus, eliminated the urban cycle of disease in the 
western hemisphere. 
 In many endemic African countries, the 
same resources have not been available to mobilize 
widespread vaccination. This inadequate vaccination 
coverage, coupled with added intermediate trans-
mission cycle, have been significant contributors to the 
much higher YF disease burden in Africa.
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